CoChat
Sign Up
Cited by 131Pharmaceutical Practices and Patient OutcomesDementia and Cognitive Impairment ResearchIntensive Care Unit Cognitive Disorders

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Cognitive Effects of Reducing Anticholinergic Drug Burden in a Frail Elderly Population: A Randomized Controlled Trial

Kersten, H., Molden, E., Tolo, I. K., Skovlund, E., Engedal, K., Wyller, T. B.·2013·The Journals of Gerontology Series A: Biological Sciences and Medical Sciences
DOI 10.1093/gerona/gls176
Open this paper in CoChat — free account

Abstract

Background Observational studies report a relationship between anticholinergic drug scale (ADS) score and cognitive function. This study investigated whether a reduced ADS score improved cognitive function in a frail elderly population. Methods This randomized, controlled, single-blinded trial, recruited long-term residents with an ADS score of greater than or equal to 3 from 22 nursing homes in Norway. The participants were randomly allocated (1:1) to intervention or control. The intervention was a pharmacist-initiated reduction of ADS score after multidisciplinary drug reviews. Primary end point was Consortium to Establish a Registry for Alzheimer's Disease 10-wordlist test for immediate recall. Secondary end points were Mini-Mental Sate Examination, delayed recall and recognition of words, saliva flow, and serum anticholinergic activity (SAA).The participants were retested after 4 and 8 weeks, and the study groups were compared after adjusting for baseline differences. Results Eighty-seven patients were included. The median ADS score was reduced by 2 units (p .18). Conclusion Pharmacist-initiated drug changes significantly reduced ADS score but did not improve cognitive function in nursing home residents. Moreover, the drug changes did not reduce SAA or mouth dryness significantly, which might indicate limited applicability of the ADS score to prevent prescription risks in this population.

Overview

Integrity signals

Registry

Crossref · 10.1093/gerona/gls176

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Evidence from anticholinergic cessation trials have not shown improvements in cognitive function, but these have been underpowered and focused on short term outcomes.

    “Evidence from anticholinergic cessation trials have not shown improvements in cognitive function, but these have been underpowered and focused on short term outcomes.40”

    From Anticholinergic drugs and risk of dementia: case-control study (2018) · cites this paper as [40]

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 38

  1. 2003, The Journals of Gerontology Series A: Biological Sciences and Medical Sciences, 58, M813, 10.1093/gerona/58.9.M813 · DOI
  2. Hanlon, 2006, The Journals of Gerontology Series A: Biological Sciences and Medical Sciences, 61, 511, 10.1093/gerona/61.5.511 · DOI
  3. 2000, The Journals of Gerontology Series A: Biological Sciences and Medical Sciences, 55, M554, 10.1093/gerona/55.10.M554 · DOI
  4. 2012, The Journals of Gerontology Series A: Biological Sciences and Medical Sciences, 67, 698
  5. Chew, 2005, American Journal of Geriatric Psychiatry, 13, 535, 10.1176/appi.ajgp.13.6.535 · DOI
  6. Wawruch, 2012, Pharmacoepidemiology and drug safety, 21, 170, 10.1002/pds.2169 · DOI
  7. Peters, 1989, Archives of Internal Medicine, 149, 2414, 10.1001/archinte.1989.00390110020006 · DOI
  8. Nebes, 2007, The Journals of Gerontology Series A: Biological Sciences and Medical Sciences, 62, 83, 10.1093/gerona/62.1.83 · DOI
  9. Chew, 2008, Journal of the American Geriatrics Society, 56, 1333, 10.1111/j.1532-5415.2008.01737.x · DOI
  10. Mulsant, 2003, Archives of General Psychiatry, 60, 198, 10.1001/archpsyc.60.2.198 · DOI
  11. Fox, 2011, Journal of the American Geriatrics Society, 59, 1477, 10.1111/j.1532-5415.2011.03491.x · DOI · Paper page
  12. Campbell, 2009, 4, 225
  13. Halvorsen, 2010, Scandinavian journal of primary health care, 28, 82, 10.3109/02813431003765455 · DOI
  14. 1998, The Journals of Gerontology Series A: Biological Sciences and Medical Sciences, 1, 59
  15. Carnahan, 2006, The Journal of Clinical Pharmacology, 46, 1481, 10.1177/0091270006292126 · DOI
  16. Marin, 2001, International journal of geriatric psychiatry, 16, 745, 10.1002/gps.385 · DOI
  17. Charlson, 1987, Journal of chronic diseases, 40, 373, 10.1016/0021-9681(87)90171-8 · DOI · Paper page
  18. Karrasch, 2005, Acta neurologica Scandinavica, 111, 172, 10.1111/j.1600-0404.2005.00380.x · DOI
  19. Braekhus, 1992, Journal of the American Geriatrics Society, 40, 1139, 10.1111/j.1532-5415.1992.tb01804.x · DOI
  20. Navazesh, 1993, Annals of the New York Academy of Sciences, 694, 72, 10.1111/j.1749-6632.1993.tb18343.x · DOI
  21. Tune, 1980, Archives of General Psychiatry, 37, 293, 10.1001/archpsyc.1980.01780160063007 · DOI
  22. Jakobsen, 2011, Journal of the American Geriatrics Society, 59, 501, 10.1111/j.1532-5415.2010.03307.x · DOI
  23. Rudolph, 2008, Archives of Internal Medicine, 168, 508, 10.1001/archinternmed.2007.106 · DOI · Paper page
  24. Han, 2008, Journal of the American Geriatrics Society, 56, 2203, 10.1111/j.1532-5415.2008.02009.x · DOI
  25. 2011, Age and Ageing, 40, 730, 10.1093/ageing/afr102 · DOI
  26. Bottiggi, 2006, American Journal of Geriatric Psychiatry, 14, 980, 10.1097/01.JGP.0000224619.87681.71 · DOI
  27. Kolanowski, 2009, Journal of the American Medical Directors Association, 10, 252, 10.1016/j.jamda.2008.11.005 · DOI
  28. Carriere, 2009, Archives of Internal Medicine, 169, 1317, 10.1001/archinternmed.2009.229 · DOI · Paper page
  29. Br bion, 2004, Psychological medicine, 34, 369, 10.1017/S0033291703008900 · DOI
  30. Hilmer, 2007, Archives of Internal Medicine, 167, 781, 10.1001/archinte.167.8.781 · DOI
  31. Cao, 2008, Clinical pharmacology and therapeutics, 83, 422, 10.1038/sj.clpt.6100303 · DOI · Paper page
  32. 2012, The Journals of Gerontology Series A: Biological Sciences and Medical Sciences, 67, 181
  33. Cancelli, 2008, Journal of clinical psychopharmacology, 28, 654, 10.1097/JCP.0b013e31818ce849 · DOI
  34. 2009, The American journal of medicine, 122, 1142, 10.1016/j.amjmed.2009.02.021 · DOI
  35. 2006, BMJ, 332, 455, 10.1136/bmj.38740.439664.DE · DOI · Paper page
  36. Lechevallier-Michel, 2005, British journal of clinical pharmacology, 59, 143, 10.1111/j.1365-2125.2004.02232.x · DOI
  37. Uusvaara, 2011, Drugs & aging, 28, 131, 10.2165/11585060-000000000-00000 · DOI
  38. Hamilton, 2009, 9, 5, 10.1186/1471-2318-9-5 · DOI

Cited by

Sorted by citations

Metadata

Authors
Kersten, H., Molden, E., Tolo, I. K., Skovlund, E., Engedal, K., & Wyller, T. B.
Affiliations
  • Oslo University Hospital (NO)
  • University of Oslo (NO)
Corresponding author
Kersten, H.
ORCID
Venue
The Journals of Gerontology Series A: Biological Sciences and Medical Sciences
Publisher
Oxford University Press (OUP)
Published
2012-09-14
Volume
68
Issue
3
Pages
271-278
ISSN
  • 1079-5006 (ISSN-L)
  • 1758-535X
DOI
10.1093/gerona/gls176
OpenAlex
W2113105425
Cited by
131
References
1
Citations by year
2026: 5 · 2025: 2 · 2024: 11 · 2023: 11 · 2022: 7 · 2021: 12 · 2020: 14 · 2019: 11 · 2018: 11 · 2017: 7 · 2016: 7 · 2015: 14 · 2014: 11 · 2013: 8
FWCI
8.59
Type
journal article
Language
en
Open access
closed
Locations
  • The Journals of Gerontology Series A (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Geriatrics and Gerontology › Pharmaceutical Practices and Patient Outcomes
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Critical Care and Intensive Care Medicine › Intensive Care Unit Cognitive Disorders
Keywords
anticholinergic burden, Anticholinergic Drug Scale, cognitive function, frail elderly, nursing home residents, anticholinergic activity, salivary flow, xerostomia, Alzheimer's disease, long-term care
MeSH terms
Aged, 80 and over, Cognition, Female, Humans, Male, Neuropsychological Tests, Nursing Homes, Pharmacists, Mental Recall, Salivation, Single-Blind Method, Frail Elderly, Drug Utilization Review, Cholinergic Antagonists

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review